R/C BUDEPRESS 400
Item requires a valid prescription
Manufactured By Steris Healthcare Pvt Ltd
Composition Budesonoid (400mcg) + Formoterol (0.6mcg)
Rs 151.00
MRP Rs 215.71
(30% OFF)
Includes all taxes
Package SIZE
( 30 Capsules )
100% Authentic
Products
Free
Shipping*
Products
Return Policy
Description:
BUDEPRESS 400 is a combination medication containing Budesonide (400mcg) and Formoterol (0.6mcg). This medication is widely used for managing asthma and chronic obstructive pulmonary disease (COPD). Budesonide is a corticosteroid that reduces inflammation in the airways, while Formoterol is a long-acting beta-agonist that helps in relaxing the muscles of the airways to improve breathing.
How Does It Work?
- Budesonide: Budesonide is a potent anti-inflammatory agent. It works by decreasing the inflammation in the lungs, thereby reducing the frequency and severity of asthma attacks.
- Formoterol: Formoterol is a long-acting bronchodilator. It works by relaxing the muscles around the airways, making it easier to breathe and preventing symptoms like wheezing and shortness of breath.
Uses of BUDEPRESS 400
- Asthma: BUDEPRESS 400 is used for the maintenance treatment of asthma. It helps in controlling symptoms and reducing the frequency of asthma attacks.
- Chronic Obstructive Pulmonary Disease (COPD): This combination is also effective in managing COPD, helping to improve breathing and reduce the exacerbations of the disease.
What is BUDEPRESS 400? BUDEPRESS 400 is an inhalation medication that combines Budesonide (400mcg) and Formoterol (0.6mcg). It is designed to be used regularly to control and prevent the symptoms of asthma and COPD. The inhaler provides a steady dose of both medications to ensure effective management of respiratory conditions.
Side Effects
- Common Side Effects:
- Headache
- Throat irritation
- Hoarseness
- Oral thrush
- Cough
- Serious Side Effects:
- Palpitations
- High blood pressure
- Increased risk of infections
- Osteoporosis
- Adrenal suppression
If You Need More Information About R/C BUDEPRESS 400 (Click here)